Zelira Therapeutics (ASX:ZLD) Net Margin %: 0.00% (As of Jun. 2025)


What is Zelira Therapeutics Net Margin %?

Zelira Therapeutics ASX:ZLD Net Margin % is 0.00% as of Jun. 2025. The stock has 7 warning signs investors should review. Among 946 Biotechnology companies, Zelira Therapeutics ranks worse than 99.05% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Zelira Therapeutics's Net Income for the six months ended in Jun. 2025 was A$-1.22 Mil. Zelira Therapeutics's Revenue for the six months ended in Jun. 2025 was A$0.00 Mil. Therefore, Zelira Therapeutics's net margin for the quarter that ended in Jun. 2025 was 0.00%.

The historical rank and industry rank for Zelira Therapeutics's Net Margin % or its related term are showing as below:

ASX:ZLD' s Net Margin % Range Over the Past 10 Years
Min: -362800   Med: -1974.36   Max: -775.15
Current: -362800

ASX:ZLD's Net Margin % is ranked worse than
99.05% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs ASX:ZLD: -362800.00

Zelira Therapeutics  (ASX:ZLD) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Zelira Therapeutics Net Margin % Related Terms

Zelira Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Net Margin % Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,974.36 -775.15 -1,851.50 -38,493.68 -362,800.00

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,025.00 -62,063.64 -6,085.00 -241,100.00 0.00

ASX:ZLD vs ENSC, PPCB, ACUT: Net Margin % Comparison

For the Biotechnology subindustry, Zelira Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelira Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's Net Margin % falls into.


Zelira Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Zelira Therapeutics's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-3.628/0.001
=-362,800.00 %

Zelira Therapeutics's Net Margin for the quarter that ended in Jun. 2025 is calculated as

Net Margin=Net Income (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-1.217/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Zelira Therapeutics (ASX:ZLD) has a Net Margin % of 0.00% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on Zelira Therapeutics and its competitors. According to the industry distribution chart, Zelira Therapeutics ranks #937 out of 946 companies in the Biotechnology industry, placing it in the top 99%.
Is Zelira Therapeutics' Net Margin % too high?
Zelira Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Zelira Therapeutics ranks #937 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Zelira Therapeutics' Net Margin % compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Zelira Therapeutics ranks #937 out of 946 companies for Net Margin %. This places Zelira Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Net Margin % of 0.00%. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Net Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.